SIGA Technologies to Host Business Update Call on August 4th, 2022 Following Release of Second Quarter 2022 Financial Results Read more about SIGA Technologies to Host Business Update Call on August 4th, 2022 Following Release of Second Quarter 2022 Financial Results We have monkeypox treatments – but must act fast Read more about We have monkeypox treatments – but must act fast SIGA Announces Oncology Collaboration with KaliVir Immunotherapeutics Read more about SIGA Announces Oncology Collaboration with KaliVir Immunotherapeutics SIGA Announces Approximately $28 Million of International Procurement Orders for Oral TPOXX® (Tecovirimat) Read more about SIGA Announces Approximately $28 Million of International Procurement Orders for Oral TPOXX® (Tecovirimat) SIGA Technologies Receives Approval from UK for Tecovirimat Read more about SIGA Technologies Receives Approval from UK for Tecovirimat SIGA Announces $13 Million of International Procurement Orders for Oral TPOXX® (Tecovirimat) Read more about SIGA Announces $13 Million of International Procurement Orders for Oral TPOXX® (Tecovirimat) SIGA to Participate in Alliance Global Partners’ Monkeypox Panel on Thursday, June 23rd 2022 Read more about SIGA to Participate in Alliance Global Partners’ Monkeypox Panel on Thursday, June 23rd 2022 How much medicine does the U.S. actually have to fight monkeypox? Read more about How much medicine does the U.S. actually have to fight monkeypox? Clinical features and management of human monkeypox: a retrospective observational study in the UK Read more about Clinical features and management of human monkeypox: a retrospective observational study in the UK Siga gets requests for smallpox drug in Europe as monkeypox spreads Read more about Siga gets requests for smallpox drug in Europe as monkeypox spreads Pagination First page « First Previous page ‹ Previous Page 1 Current page 2 Page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Page 9 … Next page Next › Last page Last » Subscribe to
SIGA Technologies to Host Business Update Call on August 4th, 2022 Following Release of Second Quarter 2022 Financial Results Read more about SIGA Technologies to Host Business Update Call on August 4th, 2022 Following Release of Second Quarter 2022 Financial Results
We have monkeypox treatments – but must act fast Read more about We have monkeypox treatments – but must act fast
SIGA Announces Oncology Collaboration with KaliVir Immunotherapeutics Read more about SIGA Announces Oncology Collaboration with KaliVir Immunotherapeutics
SIGA Announces Approximately $28 Million of International Procurement Orders for Oral TPOXX® (Tecovirimat) Read more about SIGA Announces Approximately $28 Million of International Procurement Orders for Oral TPOXX® (Tecovirimat)
SIGA Technologies Receives Approval from UK for Tecovirimat Read more about SIGA Technologies Receives Approval from UK for Tecovirimat
SIGA Announces $13 Million of International Procurement Orders for Oral TPOXX® (Tecovirimat) Read more about SIGA Announces $13 Million of International Procurement Orders for Oral TPOXX® (Tecovirimat)
SIGA to Participate in Alliance Global Partners’ Monkeypox Panel on Thursday, June 23rd 2022 Read more about SIGA to Participate in Alliance Global Partners’ Monkeypox Panel on Thursday, June 23rd 2022
How much medicine does the U.S. actually have to fight monkeypox? Read more about How much medicine does the U.S. actually have to fight monkeypox?
Clinical features and management of human monkeypox: a retrospective observational study in the UK Read more about Clinical features and management of human monkeypox: a retrospective observational study in the UK
Siga gets requests for smallpox drug in Europe as monkeypox spreads Read more about Siga gets requests for smallpox drug in Europe as monkeypox spreads